EBGLYSS = lebrikizumab-lbkz
EBGLYSS is a prescription medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.
It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).
is now approved for adults and children 12 years or older who have moderate-to-severe atopic dermatitis. Atopic dermatitis, or eczema, is characterized by itchy skin most often located on the arms or behind the knees, but which can appear anywhere.
Lebrikizumab-lbkz injection is used to treat moderate to severe atopic dermatitis (a type of eczema; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children age 12 years and older who cannot use topical medications for their condition or who have not responded to topical medications. Lebrikizumab-lbkz is in a class of medications called interleukin-13 receptor inhibitors. It works by blocking the activity of interleukin-13, a substance in the body that causes inflammation.
How should this medicine be used?
Lebrikizumab-lbkz injection comes as a solution (liquid) to be injected subcutaneously (under the skin). It is usually given as two injections every 2 weeks for the first two doses, followed by once injection every 2 weeks after the first two doses for 16 weeks, and then may be continued as one injection every 4 weeks after that. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use lebrikizumab-lbkz injection exactly as directed. Do not inject more or less of it or inject it more often than prescribed by your doctor.
You may receive your first dose of lebrikizumab-lbkz injection in your doctor's office. After that, you may be able to inject the medication yourself at home or have a friend or relative perform the injections. If you will be injecting lebrikizumab-lbkz injection subcutaneously by yourself at home or having a friend or relative inject the medication for you, your doctor will show you or the person who will be injecting the medication how to inject it. Read the written instructions for use that come with lebrikizumab-lbkz injection before you inject the medication.
Lebrikizumab-lbkz injection comes in prefilled syringes and prefilled pens. Use each syringe and pen only once and inject all the solution in the syringe or pen. Do not reuse lebrikizumab-lbkz pre-filled syringes and do not recap the syringes after use. Dispose of used syringes and pens in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.
You can inject lebrikizumab-lbkz injection on the front of your thighs (upper leg), at least 2 inches above your knee and 2 inches below your groin, or abdomen (stomach) except your navel (belly button) and the area 2 inches (5 centimeters) around it. If someone else is giving you the injection, the back of the upper arm may also be used. To reduce the chances of soreness or redness, use a different injection site for each injection. Do not inject the medication into damaged, bruised, scarred or tender skin.
If you are using a prefilled syringe or prefilled pen that has been refrigerated, place the syringe or pen on a flat surface without removing the needle cap and allow it warm to room temperature for 45 minutes before you are ready to inject the medication. Do not try to warm the medication by heating it in a microwave, placing it in hot water, or through any other method.
Do not shake a syringe or pen that contains lebrikizumab-lbkz injection.
EBGLYSS is a prescription medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.
It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).
is now approved for adults and children 12 years or older who have moderate-to-severe atopic dermatitis. Atopic dermatitis, or eczema, is characterized by itchy skin most often located on the arms or behind the knees, but which can appear anywhere.
Lebrikizumab-lbkz injection is used to treat moderate to severe atopic dermatitis (a type of eczema; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children age 12 years and older who cannot use topical medications for their condition or who have not responded to topical medications. Lebrikizumab-lbkz is in a class of medications called interleukin-13 receptor inhibitors. It works by blocking the activity of interleukin-13, a substance in the body that causes inflammation.
How should this medicine be used?
Lebrikizumab-lbkz injection comes as a solution (liquid) to be injected subcutaneously (under the skin). It is usually given as two injections every 2 weeks for the first two doses, followed by once injection every 2 weeks after the first two doses for 16 weeks, and then may be continued as one injection every 4 weeks after that. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use lebrikizumab-lbkz injection exactly as directed. Do not inject more or less of it or inject it more often than prescribed by your doctor.
You may receive your first dose of lebrikizumab-lbkz injection in your doctor's office. After that, you may be able to inject the medication yourself at home or have a friend or relative perform the injections. If you will be injecting lebrikizumab-lbkz injection subcutaneously by yourself at home or having a friend or relative inject the medication for you, your doctor will show you or the person who will be injecting the medication how to inject it. Read the written instructions for use that come with lebrikizumab-lbkz injection before you inject the medication.
Lebrikizumab-lbkz injection comes in prefilled syringes and prefilled pens. Use each syringe and pen only once and inject all the solution in the syringe or pen. Do not reuse lebrikizumab-lbkz pre-filled syringes and do not recap the syringes after use. Dispose of used syringes and pens in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.
You can inject lebrikizumab-lbkz injection on the front of your thighs (upper leg), at least 2 inches above your knee and 2 inches below your groin, or abdomen (stomach) except your navel (belly button) and the area 2 inches (5 centimeters) around it. If someone else is giving you the injection, the back of the upper arm may also be used. To reduce the chances of soreness or redness, use a different injection site for each injection. Do not inject the medication into damaged, bruised, scarred or tender skin.
If you are using a prefilled syringe or prefilled pen that has been refrigerated, place the syringe or pen on a flat surface without removing the needle cap and allow it warm to room temperature for 45 minutes before you are ready to inject the medication. Do not try to warm the medication by heating it in a microwave, placing it in hot water, or through any other method.
Do not shake a syringe or pen that contains lebrikizumab-lbkz injection.